Safety and Efficacy of a Recombinant Hepatitis E Vaccine

P. Shrestha, Mrigendra; McNair Scott, Robert; Man Joshi, Durga; P. Mammen, Mammen; Bahadur Thapa, Gyan; Thapa, Narbada; Saw Aye Myint, Khin; Fourneau, Marc; A. Kuschner, Robert; Kumar Shrestha, Sanjaya; David, M.P.; Seriwatana, J; W. Vaughn, David; Safary, Assad; P. Endy, Timothy; L. Innis, Bruce

doi:10.1056/nejmoa061847

Public

Safety and Efficacy of a Recombinant Hepatitis E Vaccine

Published in New England Journal of Medicine • Feb 28, 2007

Authors:

Mrigendra P. Shrestha

Robert McNair Scott

Durga Man Joshi

Abstract

BACKGROUND: Hepatitis E virus (HEV) is an important cause of viral hepatitis. We evaluated the safety and efficacy of an HEV recombinant protein (rHEV) vaccine in a phase 2, randomized, double-blind, placebo-controlled trial. METHODS: In Nepal, we studied 2000 healthy adults susceptible to HEV infec...

Subject

Medicine

Reactogenicity

Hepatitis A vaccine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!